Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-020 - Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
Author(s): David Spigel- Abstract
Loading... -
+
EP08.01-073 - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Author(s): Rajiv Kumar- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-045 - Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer
Author(s): Elaine Shum- Abstract
Loading... -
+
EP08.02-019 - Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Author(s): Alexander Spira- Abstract
Loading...
-
+
P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 12
- Coordinates: 8/07/2022, 17:00 - 19:00, Exhibit Hall - Hall B
-
+
P1.15-11 - Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study
Author(s): Myung-Ju Ahn- Abstract
Loading...